Trials Sponsors Conditions Drugs Pricing

Conditions

Cerebral Stroke Cerebrovascular Accident Stroke, Acute

Keywords

Cerebrovascular AccidentCerebrovascular Accident, AcuteFabry DiseaseFabry´s DiseaseAnderson-Fabry DiseaseCVA (Cerebrovascular Accident)Stroke, AcuteCerebral Stroke

Outcome Measures

Primary Outcomes (1)

analysis of the long-term course of lyso-Gb3 and its clinical correlation to the progression of the cardiomyopathy in N215S-Fabry patients
24 month

Study Arms (1)

Observation

All Patients with a diagnosis of Fabry disease with N215S

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

All Patients with a diagnosis of Fabry disease with N215S

You may qualify if:

All patients of both gender from 18 years of age with a diagnosis of Fabry disease with the mutation N215S

Sponsors & Collaborators

CENTOGENE GmbH Rostock
Industrylead

Study Sites (1)

University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration

Rostock, 18147, Germany

Biospecimen

Retention: SAMPLES WITH DNA

The laboratory examinations of the blood samples for measuring the lyso-Gb3-level will be done at the Laboratory of the Albrecht-Kossel-Institute, University of Rostock in collaboration with associated diagnostic laboratory partners. This laboratory offers an existing infrastructure, a highly standardized quality of the workflow, a short examination time of the samples and a long period of experiences in the assessment of the biological impact of mutations and polymorphism, as evidenced recently in the sifap1-study.

MeSH Terms

Conditions

StrokeFabry Disease

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesSphingolipidosesLysosomal Storage Diseases, Nervous SystemBrain Diseases, Metabolic, InbornBrain Diseases, MetabolicCerebral Small Vessel DiseasesGenetic Diseases, X-LinkedGenetic Diseases, Inborn

Study Officials

Arndt Rolfs, Prof. Dr.
CENTOGENE GmbH Rostock
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 6, 2011

First Posted

September 7, 2011

Study Start

July 1, 2011

Actual (reported)

Study Stopped

Fabry and Cardiomyopathy (FaCard)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Observation

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Observation

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations